Skip to content

Research of The Effect of Moxibustion and Acupoint Application on HIV/AIDS Immunity

Research of The Effect of Moxibustion and Acupoint Application on HIV/AIDS Immunity

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17012385
Enrollment
Unknown
Registered
2017-08-16
Start date
2017-10-08
Completion date
Unknown
Last updated
2017-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS

Interventions

Test Group:HAART+Moxibustion
Test Group:HAART+Acupoint application
Test Group:HAART+Moxibustion+Acupoint application
Control Group:HAART

Sponsors

Kunming Municipal Hospital of Traditonal Chinese Medcine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. HIV antibody tests positive by Western Blot confirmation; 2. HAART treatment time for 1 year or more; 3. CD4+ T lymphocyte counts between 200-350 cells/mm3; 4. HIV-RNA<40 copies/ml; 5. All genders, Aged 18-65 years; 6. Voluntary participation in this study was signed by informed consent.

Exclusion criteria

Exclusion criteria: Conforming to inclusion criteria, but has one of the following conditions shall be excluded: 1. The one who suffers from severe opportunistic infections; 2. Patients who are participating in other treatment studies within 3 months; 3. Patients who are receiving immunomodulatory treatment within 3 months; 4. Patients who are complicating with other diseases, such as severe cardiovascular, renal diseases, tuberculosis, malignant tumors, severe organic heart disease, severe arrhythmia, abnormal liver function (AST and ALT increased more than 2 times), and immune diseases, etc.; 5. Patients who are Suffering from serious mental and neurological problems; 6. Pregnant or lactating women; 7. Patients who allergic to moxibustion, Chinese herbal medicine or adhesive tape; 8. Patients who are mentally or mentally disabled and fails to fully understand the content of the experiment or who can not cooperate well; 9. Other reasons cannot be treated on time; 10. The researchers believe other reasons which are not appropriate for clinical trials.

Design outcomes

Primary

MeasureTime frame
CD4+, CD8+count;CD4CD45RA, RO;Th1, Th2;cytokine;Semeiology indicators;

Secondary

MeasureTime frame
HIV viral load;

Countries

China

Contacts

Public ContactChen Xin

Kunming Municipal Hospital of Traditonal Chinese Medcine

kmnnc@126.com+86 13888383345

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026